v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenues: $ 500,000 $ 54,990 $ 500,000
Operating expenses:        
Research and development 2,515,211 2,898,012 5,621,521 4,785,965
General and administrative 1,440,394 1,129,519 2,727,708 2,373,205
Total operating expenses 3,955,605 4,027,531 8,349,229 7,159,170
Operating loss (3,955,605) (3,527,531) (8,294,239) (6,659,170)
Other income (expense):        
Interest and investment income 379,521 69,877 749,991 111,453
Interest expense (7,568) (27,098)
Unrealized gain on warrant liability 27,455 583,445 125,589 205,457
Gain on litigation settlement liability 250,000 250,000
Total other income, net 406,976 895,754 875,580 539,812
Loss before income tax expense (3,548,629) (2,631,777) (7,418,659) (6,119,358)
Income tax expense (200) (200)
Net loss (3,548,629) (2,631,777) (7,418,859) (6,119,558)
Issuance of Series B preferred stock dividend (89)
Net loss attributable to common shareholders $ (3,548,629) $ (2,631,777) $ (7,418,948) $ (6,119,558)
Basic loss per share attributable to common stock $ (0.68) $ (0.50) $ (1.42) $ (1.17)
Weighted average common shares outstanding, basic 5,234,830 5,234,141 5,234,830 5,228,608
Diluted loss per share attributable to common stock $ (0.68) $ (0.61) $ (1.44) $ (1.20)
Weighted average common shares outstanding, diluted 5,234,830 5,263,389 5,234,830 5,262,993
Comprehensive loss:        
Net unrealized gain (loss) on available-for-sale securities $ (19,053) $ (17,491) $ 4,509 $ (66,891)
Comprehensive loss $ (3,567,682) $ (2,649,268) $ (7,414,350) $ (6,186,449)